E. David Crawford
E David Crawford, MD
Professor of Radiation Oncology
  • :720-848-0195
    • :- 720-848-0203

University of Colorado
USA

Education

College:

  • University of Cincinnati, Cincinnati, Ohio       BS 1969 (Chemistry)

Medical School:

  • University of Cincinnati, Cincinnati, Ohio       MD 1973

Postgraduate Training
Internship:

  • Good Samaritan Hospital, Department of Surgery,      1973-74
    Cincinnati, Ohio

Residency:

  • Good Samaritan Hospital, Department of Surgery,      1974-77
    Cincinnati, Ohio

Fellowship:

  • Clinical Fellow in Urology under auspices of  1977-78
    Dr. Donald G Skinner, University of California
    Medical Center, Los Angeles, California

 

Biography

Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher. He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the county by Men's Health Magazine, and recently selected as the Healthcare Provider of the Year in the Denver Metro Area by The Denver Business Journal. In addition, he is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 600 published articles, contributed to nearly 100 educational books and provided thousands of educational talks for patients and physicians. In an effort to raise awareness and education about prostate health, Dr. Crawford also founded and chairs a 501c3 non-profit called the Prostate Conditions Education Council.
Dr. Crawford is also the founder and Chairman of the Prostate Conditions Education Council which is responsible for reaching an average of 400 million people each year with education and awareness information.
On prostate cancer and men's health issues, his involvement in the national prostate cancer arena has been widely recognized and he is often requested to act as an educator, speaker, participate in advisory boards, review research or serve as a legal expert.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science.

Research Interest

I am interested in Prostate, Bladder, Renal and Testicular Cancer and Benign Prostatic Enlargement. I have been a key developer of staging biopsies for prostate cancer and minimally invasive therapy.

Professional Activities:

Academic Appointments

Lecturer in Surgery University of California Medical Center, Los Angeles, California 1977-78
Assistant Professor of Urology University of New Mexico School of Medicine, Albuquerque, New Mexico 1978-82
Associate Professor of Urology University of New Mexico     
School of Medicine, Albuquerque, New Mexico 		1982-83
Director of GU Oncology University of New Mexico School of Medicine, Albuquerque, New Mexico 1979-83
Chief of Urology Cancer Research and Treatment Center, Albuquerque, New Mexico 1979-83
Associate Professor of Surgery/Urology Division of Urology, University of Mississippi Medical Center, Jackson, Mississippi 1983-85
Director, Urologic-Oncology University of Mississippi Medical Center, Jackson, Mississippi 1983-86
Attending Physician Division of Urology, Veterans Administration Hospital, Jackson, Mississippi 1983-86
Professor of Surgery/Urology Division of Urology, University of Mississippi Medical Center,
Jackson, Mississippi 		1985-86
Professor and Chairman Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 1986 -1996
Director, Clinical Cancer Unit University of Colorado Health Sciences Center, Denver, Colorado 1987-1999
Associate Director University of Colorado Cancer Center, Denver, Colorado 1987-Present
Professor of Surgery and Radiation Oncology Chair, Division of Urologic Oncology, Denver, Colorado 1999-Present
Senior Associate Director for Clinical and Community Development University of Colorado Cancer Center, Denver, Colorado 2002-Present

Specialty Certification

  • Board Certified, American Board of Urology, 1980

Visiting Professor

  1. Georgia Baptist Medical Center, June 1982
  2. University of Mississippi, June 1983
  3. Touro Infirmary, December 1983
  4. University of Utah, December 1986
  5. University of Kansas, February 1987
  6. University of Cincinnati, November 30, 1987
  7. Baylor University, March 8, 1988
  8. Louisiana State University, April 15-16, 1988
  9. University of Arkansas, September 8-9, 1988
  10. Louisiana State University, November 9-11, 1988
  11. University of California, Irvine, January 19, 1989
  12. St. Louis University, August 21, 1989
  13. Wayne State University, March 7, 1990
  14. Ohio State University, March 10, 1990
  15. Tufts University, September 6-8, 1990
  16. University of Washington, April 6, 1991
  17. Royal Society of Medicine, London, April 24-26, 1991
  18. Louisiana State University-Schreveport, October 3, 1991
  19. University of Tennessee- July 28, 1992.
  20. Vanderbilt University, April 8-9, 1994.
  21. University of Nebraska, April 22-23, 1994.
  22. Duke University, Sep 13, 1994.
  23. University of California at Davis, July 27, 1995.
  24. University of Gratz, Gratz, Austria, October 16-17, 1995.
  25. Tulane University, New Orleans, Louisiana, January 18-19, 1996.
  26. New York University, New York City, April 17, 1996.
  27. University of Nijmegen, Nijmegen, The Netherlands, June 3-6, 1996.
  28. Brown University, Providence, Rhode Island, October 9-10, 1997.
  29. Sixth Annual Hershey Visiting Professor, Harvard Medical School, Boston, MA, November 12-13, 2002
  30. Washington University in St. Louis, School of Medicine, St. Louis, MO, September 17, 2004.
  31. Brown University, Boston, MA, April 18, 2006.
  32. University of Toronto, Toronto, Canada, April 26-27, 2007.
  33. Wake Forest School of Medicine, Winston-Salem, NC, May 4-5, 2012.
  34. Thomas Jefferson University, Philadelphia, PA, June 1, 2012.
  35. Arkansas Urological, Little Rock, AK, September 27, 2012.
  36. UCSD Moores Cancer Center, La Jolla, CA, Feb 20, 2013.

Honors And Awards

  • Bachelor of Science Degree with Honors in Chemistry, University of Cincinnati, 1969
  • Phi Lamda Upsilon Honorary Chemistry Fraternity, University of Cincinnati, 1968
  • Alpha Omega Alpha, University of Cincinnati School of Medicine, 1972
  • Health Profession Scholarship, University of Cincinnati School of Medicine, 1970-1973
  • Chairman, GU Committee, Southwest Oncology Group, 1980-present
  • Chairman, Intergroup Prostate Cancer Study, 1984-1989
  • National Prostate Cancer Education Council, 1989
  • National Prostate Cancer Education Council, Chairman, 1990-present
  • Honorary Member, Leicester Medical Society, Leicester, England, 1993
  • Cited in The Best Doctors in America 1992-93, 1993-94, 1994-95, 1996-97, 1998-99, 2000-2012.
  • Cited in “Town & Country’s” Best Medical Specialists in North America, 1995
  • Cited in International Who’s Who of Professional Specialties, 1997, 1998, 2000-2004.
  • “Freddie Award” for ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), hosted by E. David Crawford with special guest retired General Norman Schwarzkopf. Presented at the 1997 AMA International Health & Medical Film Competition.
  • American Cancer Society’s televised “A Journey of Hope”, June 16, 1999.
  • CaP Cure Annual Award for Scientific Presentation. Co-recipient at Annual American Urological Association Meeting, 1999.
  • The National Registry of Who’s Who – Life Member, 1999. (registry #146620)
  • The National Registry of Who’s Who, 2000, 2001
  • “Freddie Award” for ITV: 2nd episode of Advanced Prostate Cancer Show. Time Warner, November, 2000.
  • America’s Top Physicians, Guide to America’s Top Physicians Consumer’s Research Council of America, Urologic Oncology, 2003, 2004.
  • “Champions in Healthcare Award,” Top Healthcare Provider, Denver Metropolitan Area, Denver Business Journal and Anthem Blue Cross and Blue Shield, 2006.
  • America’s Top Doctors for Men, Men’s Health Magazine, March 24, 2007.
  • Global Clinical Research & Development Certificate, January, 2008.
  • “Legends in Urology,” The Canadian Journal of Urology, June, 2008.
  • Best of Posters Award, “Use of PSA Threshold to identify an increased 4-year risk of a prostate cancer diagnosis in US men”, American Urologic Association meeting, Chicago, IL, 2009.
  • Scientific and Advisory Board Committee, 7th Men’s Health World Congress, 2010.
  • Robert J. Krane Prize for the Best Clinical Paper “Prostate danger zone.”, British Journal of Urology, 2011.

 

Publications

Recent Peer Reviewed Journals

2010

  1. Crawford ED, Black L, Eaddy M, Kruep EJ.  A Retrospective Analysis Illustrating the Substantial Clinical and Economic Burden of Prostate Cancer.  Prostate Cancer and Prostatic Diseases, 1-6, 2010.
  2. Rove KO, Sullivan KF, Crawford ED.  High Intensity Focused Ultrasound:  Ready for Primetime.  Urol Clin North Am, 37(1):27-35, 2010.
  3. Laiyemo AO, Doubin C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD.  Race and Colorectal Cancer Disparities:  Health-Care Utilization vs Different Cancer Susceptibilities.  J Natl Cancer Inst, 102:1-9, 2010.
  4. Flaig TW, Kondo KL, LaRosa FG, Kavanagh B, Crawford ED.  A Young Woman with Multiple Kidney Lesions.  Oncology 24(3):282-286, 2010.
  5. Akduman B, Tandberg DJ, O’Donnell CI, Hughes A, Moyad MA, Crawford ED.  Effect of Statins on Serum Prostate-specific Antigen Levels.  Urology 76:1048-1051, 2010.
  6. Crawford ED, Grubb R III, Black A, Andriole GL, Chen M-H, Izmirlian G, Berg CD, D’Amico AV.  Comorbidity and Mortality Results from a Randomized Prostate Cancer Screening Trial.  J Clin Onc 29:355-361, 2010.
  7. Shore ND, Crawford ED.  Intermittent Androgen Deprivation Therapy:  Redefining the Standard of Care?  Rev Urol 12(1):1-11, 2010.
  8. Prokunina-Olsson L, Fu Y-P, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Gronberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M.  Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2.  Cancer Epidemiol Biomarker Prev 19(5): 1349-1355, 2010.
  9. Crawford ED, Rove KO.  Incomplete testosterone suppression in prostate cancer.  N Engl J Med 363:1976, 2010.
  10. Crawford ED, Petrylak D.  Castration-resistant prostate cancer: descriptive yet pejorative?  J Clin Oncol 28:7664, 2010.
  11. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, DeVere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?  A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).  British J Urol 10:1464, 2010.
  12. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J.  A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-1 and IGFBP-3 blood levels and prostate cancer risk among Caucasians.  Hum Mol genet 1;19(15):3089-3101, 2010.
  13. Koutros S, Schumacher FR, Hayes RB, Ma J, Huang WY, Albanes D, Canzian F, Chanock SJ, Crawford ED, Diver WR, Feigelson HS, Giovanucci E, Haiman CA, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Riboli E, Siddiq A, Stampfer MJ, Stram DO, Thomas G, Travis RC, Thun MJ, Yeager M, Berndt SI.  Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.  Cancer Res 15;70(6):2389-2396, 2010.
  14. Flaig TW, Glode LM, Gustafson D, Van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M.  A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.  Prostate 1;70(8):848-855, 2010.
  15. Crawford ED, Andriole GL, Marberger M, Rittmaster RS.  Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.  Urology 75(3):502-509, 2010.
  16. Schroder FJ, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE.  Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide:  results from a 12-month, comparative, phase III study.  British J Urol 106(2):182-187, 2010.
  17. Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.  Eur Urol 57(5):836-842, 2010.
  18. Petrylak DP, Tangen CM, VanVeldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED.  Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.  British J Urol 105(3):317-321, 2010.
  19. Rove KO, Crawford ED. Metastatic Cancer in Solid Tumors and Clinical Outcome: Skeletal-Related Events. Cancer Network, 2010.

2011

  1. Rove KO, Crawford ED.  Dutasteride:  Novel Milestones in Prostate Cancer Chemoprevention.  Drugs of Today 47(2):135-144, 2011.
  2. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu J-L, Prorok PC, Gohagan JK, Berg CD.  Effect of Screening on Ovarian Cancer Mortality – The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.  Journal of the American Medical Association 305(22):2295-2303, 2011.
  3. Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood Jr DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.  Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy:  SWOG S9921 Study.  J Clin Oncol 29:2040-2045, 2011.
  4. Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF Jr., Hunter DJ, Thomas G, Chanock SJ.  Large-scale fine mapping of the HNF1B locus and prostate cancer risk.  Hum Mol Genet 20(16): 3322-29, 2011.
  5. Barqawi AB, Rove KO, Gholizadeh S, O’Donnell CL, Koul H, Crawford ED.  The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer.  J Urol 186:80-85, 2011.
  6. Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SL, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Gronberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF Jr., Hunter DJ, Thomas G, Chatterjee N, Chanock SJ.  Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer.  Hum Mol Genet 20(14):2869-78, 2011.
  7. Barqawi AB, Turcanu R, Gamito EJ, Lucia MS, O’Donnell CI, Crawford ED, LaRosa DD, LaRosa FG.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.  Int J Clin Exp Pathol 4(5):468-475, 2011.
  8. Crawford ED, O’Donnell CI, Barqawi AB, O’Leary M, Sullivan KF, Hughes A, Roehrborn CG, Maroni P.  Validation of the Modified American Urological Association Symptom Score.  J Urol 186:945-948, 2011.
  9. Barqawi AB, Sullivan KF, Crawford ED, Roehrborn CG, Hughes A, O’Leary M, Stone N, O’Donnell CI.  Methods of Developing UWIN, the Modified American Urological Association Symptom Score.  J Urol 186:940-944, 2011.
  10. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Mynderse LA, Roehrborn CG, Smith CP Bruskewitz R.  Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia:  A Phase II Randomized Clinical Trial.  J Urol 186:965-970, 2011.
  11. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Moul JW, Jensen J-K, Olesen TK, Persson B-E.  A Phase III Extension Trial with a 1-Arm Crossover From Leuprolide to Degarelix:  Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer.J Urol 186:889-897, 2011.
  12. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, and McVary KT.  Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms: A Randomized Trial.Journal of the American Medical Association 306(12):1344-1351, 2011.
  13. Pohlman GD, Pohlman EA, Crawford ED. Dutasteride: A Review of its Use in the Management of Prostate Disorders.Clinical Medicine Insights: Therapeutics, 2011:3.
  14. Oken MM, Hocking WG, Kvale PA, Andirole GA, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD.  Screening by Chest Radiography and Lung Cancer Morality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial.The Journal of the American Medical Association 306(17): 1865-1873, 2011.
  15. Kirby M, Hirst C, Crawford ED. Characterizing the Castration-Resistant Prostate Cancer Population: A Systematic Review. Int J Clin Pract 65:1180-1192, 2011.
  16. Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. Prostate-specific Antigen 1.5-4.0ng/mL: a diagnostic challenge and danger zone. BJU International 108:1743-1749, 2011.
  17. Higano CS, Crawford ED. New and Emerging Agents for the Treatment of Castration-Resistant Prostate Cancer. Urologic Oncology 29(6): S1-S8, 2011.
  18. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaxiano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917. AACR 4:1761-1769, 2011.
  19. Philips JM, Crawford ED. Prostate-specific antigen (PSA) screening: has the pendulum swung too far? Asian Journal of Andrology 13:655-656, 2011.
  20. Croswell JM, Kramer BS, Crawford ED.Screening for Prostate Cancer With PSA Testing: Current Status and Future Directions. Oncology4(5):468-75, 2011.
  21. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Olama AA, Kote-Jarai Z, Guy M, Severi G, Gronberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Driver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Marchand LL, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Feigelson HS, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P. Genome-wide association study identifies new prostate cancer susceptibility loci.  Herman Molecular Genetics 20(19):3867-75, 2011.
  22. Crawford ED, Phillips JM.Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manaement and Research 3:201-209, 2011.
  23. Warehera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T. Proliferative Tumor Doubling Times of Prostatic Carcinoma. Prostate Cancer 2011:301850, 2011.
  24. Maroni P, Crawford ED. Assessment of Men before Androgen Deprivation Therapy. Journal of Urology 186:371-372, 2011.
  25. Rove KO, Crawford ED.  Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.  World J Urol 2011.
  26. Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED.  Testosterone in prostate cancer: the Bethesda consensus. BJU International 2011.
  27. Rove KO, Crawford ED. Evolution of Treatment Options for Patients with CRPC and Bone Metasteses: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology 25 (14): 1362-1387, 2011.
  28. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. NEJM 365(5): 395-409, 2011.
  29. Crawford ED, Moul JW, Shore N, Meulen E, Persson B.  Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix Versus Degarelix Following Leuprolide Treatment.  The Journal of Urology 184 (4S): e289-90, 2011.

2012

  1. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohgan JK, Prorok PC. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Morality Results after 13 Years of Follow-up.  JNCI 104 (2): 1-8, 2012.
  2. Crawford ED, Flaig TW. Optimizing Outcomes of Advanced Prostate Cancer: drug sequencing and novel therapeutic approaches. Oncology 26(1): 70-77, 2012.
  3. Burglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, White RD, Hemstreet GP, Crawford ED, Thompson IM, Klein EA.  Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Rostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109. Urology79(3):633-7, 2012.
  4. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD, PLCO Project Team. Flexible Sigmoidoscopy in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: Added Yield from a Second Screening Examination. JNCI 104 (4): 280-289, 2012.
  5. Rove KO, Crawford ED. Editorial Comment: Accuracy of Primary Systematic Template Guided Transperineal Biopsy of the Prostate for Locating Prostate Cancer: A Comparison With Radical Prostectomy Specimens. The Journal of Urology 187: 2044-50, 2012.
  6. Lindstrom S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, Andriole G, Berndt SI, Boeing H, Bueno-de-Mesquita, Crawford ED, et al. Common Genetic Variants in Prostate Cancer Risk Prediction- Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).  Cancer Epidemiol Biomarkers Prev 21 (3):437-444, 2012.
  7. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, et al. Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy. The New England Journal of Medicine 366 (25):2345-2357.
  8. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Role of Testosterone in Managing Advanced Prostate Cancer. Urology 80: 754-762, 2012.
  9. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H. Projecting Prostate Cancer Mortality in the PCPT and REDUCE Chemoprevention Trials. Cancer 2012.
  10. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346). The Journal of Urology 188: 1164-1169, 2012.
  11. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Grover WL, Bostwick DG. Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases. The Journal of Urology 188(5):1726-31, 2012.
  12. Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O’Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. Optimization of Prostate Cancer Diagnosis by Increasing the Number of Core Biopsies Based on Gland Volume. Int J Clin Exp Pathol 5(9):892:899, 2012.
  13. Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen Deprivation Therapy: Past, Present and Future. BJUI Supplement 6: 1-12, 2012.
  14. Rove, KO, Crawford ED. Advanced Prostate Cancer Management. Hospital Physician Board Review Manual 15(1):1-12, 2012.
  15. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three-Dimensional Reconstruction of Prostatectomy Specimens. Prostate, 2012.
  16. Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New Considerations for ADT in Advanced Prostate Cancer and the Emerging role of GNRH antagonists. Prostate Cancer and Prostatic Diseases. 1-9, 2012.
  17. Helfand BT, Lee JY, Sharp V, Foster H, Naslund M, Williams OD, McVary KT, CAMUS Study Group. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. J Urol 188(6):2288-93, 2012.
  18. Crawford ED, Rove KO. Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications. Am J Manag Care 18(5):SP250-3, 2012.

2013

  1. Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A, CAMUS Study Group. The Effects of Increasing Doses of Saw Palmetto Fruit Extract on Serum Prostate Specific Antigen: Analysis of the CAMUS Randomized Trial. Journal of Urology 189(2): 486-92, 2013.
  2. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Sundaram SK, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Waishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM.  Intermittent verus Continuous Androgen Deprivation in Prostate Cancer. NEJM 368: 1314-25, 2013.
  3. Rove KO, Crawford ED. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. Current Opinion Urology. 23(3):208-213, 2013.
  4. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC.  Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Reviews 13(2): 251-259, 2013.
  5. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC.  Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.  Expert Reviews 13(2): 261-270, 2013.
  6. Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. Association Between Race and Follow-Up Diagnostic Care After a Positive Prostate Cancer Screening Test in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.  Cancer. 1-7, 2013.
  7. Barry MJ, Cantor A, Roehrborn CG, for the CAMUS Study Group (Crawford ED, PI, University of Colorado). Relationships Among Participant International Prostate Symptom Score, Benign Prostatic Hyperplasia Impact Index Changes and Global Ratings of Change in a Trial of Phytotherapy in Men with Lower Urinary Tract Symptoms.  J Urol 189: 987-992, 2013.
  8. Crawford ED, Eisner J, Persson BE. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 189(3):987-92, 2013.
  9. Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindstrom S, Albanes D, Ziegler RG, McCullough ML, Siddiq A, Barricarte A, Berndt SI, Buenode-Mesquita HB, Chanock SJ, Crawford ED, Diver WR, Gapstur SM, Giovannucci E, GU F, Haiman CA, Hayes RB, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Overvad K, Polidoro S, Riboli E, Schumacher FR, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Key TJ. Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCl Breast and Prostate Cancer Cohort Consortium. Int J Cancer 133(2):495-504, 2013.
  10. Tombal B, Crawford ED. Landmarks in hormonal therapy for prostate cancer. BJU Int. 111(3):E12-3, 2013.
  11. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 112(5):548-60, 2013.
  12. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J, National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 369(10):920-31, 2013.
  13. Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, van Bokhoven A, Lucia MS, Kim FJ. Anterior tumors of the prostate: diagnosis and significance. Can J Urol 20(5):6897-906, 2013.
  14. Wiedel C, Pohlman G, Arangua P, Crawford ED. Definice vhodného Kandidáta s karcinomem prostaty pro pozorování a pro cilenou fokální terapii. Urologické listy 11(3)6-12, 2013.
  15. Krughoff K, Eid k, Phillips J, Stoimenova D, Smith D, O’Donnell C, Crawford ED, Barqawi A. The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound- Guided Biopsy Compared to 3-Dimensional Transperineal Approach. Advances in Urology 10.1155/2013/249080, 2013.

2014

  1. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP, and the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer. Urology 83(3):664-669, 2014.
  2. Shui IM, Lindstrom S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Marchand LL, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. European Association of Urology 0302-2838, 2014.
  3. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized clinical Trials of Degarelix Verus Luteinising Hormone-releasing Hormone Agonists. European Association of Urology 0302-2838, 2014.
  4. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer: Results from an ongoing registry. Current Medical Research & Opinion (In Process).
  5. Barqawi AB, Stoimenova D, Krughoff K, Eid K, O’Donnell C, Phillips JM, Crawford ED.  Targeted Focal Therapy for the Management of Organ Confined Prostate Cancer. JUrol 749-753, 2014.
  6. Crawford ED, Shore ND, Mlul JW, Tombal B, Schroder FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Koltz L. Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix. Elsevier 1122-1128, 2014.
  7. Rusthoven CG, Calrson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Popular-Based Study. International Journal of Radiation Oncology 1064-73, 2014.
  8. Crawford ED, Bo-Eric Persson. Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadortropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Association of Urology e34-e35, 2014.
  9. Crawford ED, Ventii K, Shore ND. New Biomarkers in Prostate Cancer. Oncology 135-42, 2014.
  10. Rove KO, Crawford ED, Perachino M, et al. Maximal Testosterone Supression in Prostate Cancer- Free vs Total Testosterone. Urology 1217-22, 2014.
  11. Rove KO, Crawford ED. Traditional androgen abliation approaches advanced prostate cancer: new insights. The Canadian Journal of Urology 14-21, 2014.
  12. Pokharel SS, Patel NU, Garg K, La Rosa FG, Arangua P, Jones C, Crawford ED. Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transerineal mapping biopsy. Abdom Imaging, 2014.
  13. Stone NN, Miner M, Poage WL, Patel A, Crawford ED. Male Androgen Deficiency Syndrome Screening Questionnaire: A Simplified Instrument to Identify Testosterone-Deficient Men. Journal of Men’s Health 11(1) 28-37, 2014.
  14. Koo PJ, Crawford ED. ¹⁸F-NaF PRT/CT and ¹¹C-choline PET/CT for the initial detection of metastaticdisease in prostate cancer: overview and potential utilization. Oncology (Williston Park)  28(12): 1057-62, 1065-5, 2014
  15. Crawford ED, Rove KO, Schally AV, et al. The role of the FSH system in the development and progression of prostate cancer.The American Journal of Hematology Oncology. 10(6): 5-13, 2014
  16. Werahera P, Crawford ED. Diagnosis of High Grade Prostatic Cancer Using Diffuse Reflectance Spectroscopy. Journal of Urology, MP53-13. 191:4S, e593. 2014

2015

  1. Crawford ED, Moul JW.  ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.Oncology (Williston Park)  29(1): 55-8, 65-6, 2015
  2. Stone NN, Crawford ED. To screen or nor to screen: the prostate cancer dilemma. Asian Journal of Andrology 17; 44-45, 2015.
  3. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. British Journal of Urology 115(2):188-97, 2015
  4. Crawford ED, Poage W, Nyhuis A, Price D, Dowsett S, Muram D. Effects of Testosterone Level on Lower Urinary Tract Symptoms. American Journal of Men’s Health. June 14, 2015

Book Chapters

  1. Crawford ED, and Borden TA: Genitourinary Tumors. In Conn's CurrentTherapy, pp. 597-610, 1981.
  2. Crawford ED and Borden TA, Editors, Genitourinary Cancer Surgery. Philadelphia, Lea & Febiger, pp. 554, 1982.
  3. Crawford ED: Radical retropubic prostatectomy: Modified Campbell Technique. In Genitourinary Cancer Surgery. Edited by E.D Crawford and TA Borden. Philadelphia, Lea & Febiger, 1982, pp. 153-165.
  4. Crawford ED and Scardino PT: Testicular carcinoma: An overview. In Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 249-261, 1982.
  5. Kiker JD and Crawford ED: Partial cystectomy. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 217-222, 1982.
  6. Crawford ED: Salvage cystectomy after irradiation therapy. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 223-225, 1982.
  7. Crawford ED: Chemotherapy of testicular carcinoma. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 379-386, 1982.
  8. Crawford ED: Loop-end ileostomy. In Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 240-245, 1982.
  9. Crawford ED: Bladder carcinoma: An overview. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, 1982, pp. 191-198.
  10. Crawford ED: Ilioinguinal lymphadenectomy. Urology Clinics of North America 11:543, 1984.
  11. Crawford ED: Radical cystectomy and urinary diversion. In: Modern Technics in Surgery. Futura Publishing Co, pp. 30-1, 1984.
  12. Smith JA, Jr., and Crawford ED: Southwest Oncology Group experience with randomized protocols for bladder cancer. In: Controlled Clinical Trials in Urologic Oncology. Edited by L Denis, G Murphy, G Prout, and F Schroeder. New York, Raven Press, pp. 249-254, 1984.
  13. Crawford ED, Davis MA, Ahmann R, and Levasseur YJ: Objective responses and adrenocorticosteroid levels in castrated men with prostate cancer treated with aminoglutethimide plus hydrocortisone. In: Recent Advances in Chemotherapy. Edited by J Ishigami. Tokyo, University of Tokyo Press, p. 1180, 1985.
  14. Crawford ED, Samson M, Klugo RC, Dawkins CA, and Davis MA: High-dose versus low-dose Cisplatin combined with vinblastine and bleomycin and selective surgical resection of residual disease in patients with disseminated testicular cancer: A Southwest Oncology Group Study. In: Testicular Cancer. Edited by S Khoury, R Kuss, G Murphy, and AR Liss. New York, 1986.
  15. Smith RA and Crawford ED: Cost implications of transurethral prostatectomy in cost-effective surgery. Edited by B Eiseman, p. 271, 1986.
  16. Williams SD, Stabelin D, Muggia F, Einhorn LH, Hahn R, Donohue JP, Brunner K, DeWys W, Crawford ED, et al.: Early stage testis cancer. The Testicular Cancer Intergroup Studies. In Adjuvant Therapy of Cancer V. SE. Salmon, editor. New York, Grune & Stratton, Inc., pp. 587-592, 1987.
  17. Crawford ED and Davis MA: Management of non-transitional cell tumors of the bladder. In Genitourinary Cancer Management. Edited by DF Paulson and JB deKernion. Philadelphia, Lea & Febiger, pp. 95-106, 1987.
  18. Crawford ED: Interstitial testicular cell tumors. In Current Therapy in Genitourinary Cancer. Edited by MJ Resnick and ED Kursh. St. Louis, CV. Mosby Company, 1987.
  19. Crawford ED, Ahmann FR, Davis MA, and Levasseur Y: Aminoglutethimide in metastatic adenocarcinoma of the prostate. In Prostate Cancer: Research, Endocrine Treatment, and Histopathology. pp. 283-289, 1987.
  20. Crawford ED, Das S, and Smith JA: Preoperative radiation therapy in the treatment of bladder cancer. Controversies in urologic oncology. Urology Clinics North America 14(4):781-787, 1987.
  21. Crawford ED and Dawkins CA: Management of carcinoma of the penis. In Genitourinary Cancer. Edited by DG Skinner. Philadelphia, W.B. Saunders, p. 549, 1988.
  22. Crawford ED: Ilioinguinal lymphadenectomy. In Genitourinary Cancer. Edited by DG Skinner. Philadelphia, W.B. Saunders, p. 817. 1988.
  23. Crawford ED and Davis MA: Luetinizing hormone-hormone releasing analogues in the treatment of prostate cancer. In: Endocrine Therapies in Breast and Prostate Cancer. Edited by CK Osborne. Boston, Kluwer Academic Publishers, pp. 25-38, 1988.
  24. Crawford ED, Ahmann FR, Kreis W, Davis MA, and Levasseur YJ: Aminoglutethimide plus hydrocortisone in the treatment of castration-refractory advanced adenocarcinoma of the prostate. In: Hormonal Therapy of Prostate Diseases: Basic and Clinical Aspects. Edited by M. Motta and M. Serio. The Netherlands, Medicom Europe, pp. 353-360, 1988.
  25. Einhorn LH, Crawford ED, Shipley WU, Loehrer PJ, and Williams SD: Cancer of the testes. In: Cancer Principles and Practice of Oncology, Vol. 1. Edited by VT DeVita, S. Hellman, and S.A Rosenberg. Philadelphia, J B. Lippincott Company, pp. 1071-1098, 1989.
  26. Crawford ED: Derzeitige konzepte in der behandlung des fortgeschrittenen prostatakarzinoms und zwischenbericht uber die phase III studie leuprorelin plus plazebo vs leuprorelin plus flutamid der South Western Oncology Group 8494. In: Therapie des forgeschrittenen Prostatakarzinoms. Edited by JE. Altwein and G Bartsch. Frankfurt, Germany, pp. 46-65, 1989.
  27. Lamm DL, Crissmann J, Blumenstein B, Crawford ED, et al.: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. In: Progress in Clinical and Biological Research Volume 310: EORTC Genitourinary Group Monograph 6--BCG in Superficial Bladder Cancer. Edited by FMJ Debruyne, L Denis, APM van der Meijden. New York: Alan R. Liss, Inc., pp. 263-270, 1989.
  28. Pfister RR and Crawford ED: Disorders of the testes. In: Operative Surgery, 3d ed. Edited by PF Nora. Philadelphia, W. B. Saunders Company, pp. 1156-1189, 1990.
  29. Heppe RK and Crawford ED: Radical nephrectomy: Thoracoabdominal intrapleural approach. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 39-44, 1990.
  30. Crawford ED: Radical retropubic prostatectomy: Antegrade approach. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 180-192, 1990.
  31. Mayer F and Crawford ED: Partial cystectomy. In: Current GenitourinaryCancer Surgery. Edited by E.D Crawford and S Das. Philadelphia, Lea & Febiger, pp 247-252, 1990.
  32. Nabors W and Crawford ED: Salvage cystectomy after irradiation failure. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 253-256, 1990.
  33. Das S and Crawford ED: Carcinoma of the penis: Management of the primary. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 367-372, 1990.
  34. Das S and Crawford ED: Carcinoma of the penis: Management of the regional lymphatic drainage. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 373-379, 1990.
  35. Das S and Crawford ED: Hormonal therapy of advanced carcinoma of the prostate. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp. 499-506, 1990.
  36. Crawford ED, Natale RB, and Grossman HB: Southwest Oncology Group Study 8710: Trial of cystectomy alone versus neoadjuvant MVAC and cystectomy in patients with locally advanced bladder cancer. In: NeoadjuvantChemotherapy in Invasive Bladder Cancer. Edited by TAW Splinter and HI Scher. New York, Wiley-Liss, Inc., pp. 111-113, 1990.
  37. Weiner S and Crawford ED: Complications of retroperitoneal lymphadenectomy. In Complications of Urologic Surgery: Prevention andManagement, 2nd ed. Edited by R.B Smith and R.M Ehrlich. Philadelphia, W. B. Saunders, pp. 286, 1990.
  38. Nabors W and Crawford ED: Carcinoma of the prostate. In: Conn's Current Diagnosis. Philadelphia, W. B. Saunders, pp.1185-1187, 1990.
  39. Foote JE. and Crawford ED: Combined hormonal therapy in the management of adenocarcinoma of the prostate. In: Problems in Urology. Edited by DF Paulson. Philadelphia, J B. Lippincott, pp. 473-488, 1990.
  40. Donohue RE, Davis MA, and Crawford ED: Diseases of the prostate. In: Geriatric Medicine. RW Schrier, editor. Philadelphia, W. B. Saunders, pp. 168-178, 1990.
  41. Nabors W and Crawford ED: Malignant tumors of the urogenital tract. In: Conn's Current Therapy. Edited by R.E. Rakel. Philadelphia, W.B. Saunders. 1991.
  42. Crawford ED: Radical cystectomy and urinary diversion. In: Current Operative Urology 1991. Edited by ED Whitehead. Philadelphia, J B. Lippincott, pp. 181-196, 1991.
  43. Westmacott R and Crawford ED: Commentary: Radical cystectomy. In: Current Operative Urology 1991. Edited by E.D Whitehead. Philadelphia, J B. Lippincott, pp. 197-200, 1991.
  44. Crawford ED and Heppe RK: Nephrectomy and nephroureterectomy. In: Urologic Surgery, 4th ed. Edited by J Glenn. Philadelphia, J B. Lippincott, pp. 22-41, 1991.
  45. Crawford ED and Nabors WL: Total androgen ablation: American experience. Urol Clinics of No. Am., 18(1):55-63, 1991.
  46. Thrasher B and Crawford ED: Minimally invasive transitional cell carcinoma. In Current Therapy in Genitourinary Surgery, 2nd edition. Edited by MA Resnick and ED Kursh New York, BC Decker, pp.74-78, 1991.
  47. Leddy FF and Crawford ED: Pelvic and Inguinal Lymphadenectomy. In Surgical Management of Urologic Disease, An Anantomic Approach. Edited by MJ Droller. Mosby Year Book, pp. 677-90, 1992.
  48. Thrasher JB and Crawford ED: Management of Invasive and Metastatic Bladder Cancer.In: Current Problems in Urology.Edited by LL Lipshultz. St. Louis, Mosby, 2:35-65, 1992.
  49. Thrasher JD and Crawford,ED: Complication of Intravesical Chemotherapy. In: Urologic Clinics of North America ,19(3) 529-539.
  50. Quinones D, Crawford ED: Seminal Vesiculectomy. In: Urologic Surgery. Ed. Fowler, JE. Boston/Toronto/London, Little, Brown and Co.
  51. Crawford ED, and Das S: Penile, Urethral and Scrotal Cancer. In: The Urologic Clinics of North America, vol 19(2). W.B Saunders Co., 1992.
  52. Crawford,ED and Daneshgari F: Leuprolide/Leuprolein. In: Therapeutic Drugs. Edited by Sir Colin Dollery, Churchill and Livingstone, 1992.
  53. Crawford ED and DeAntoni EP: PSA as a Screening Test for Prostate Cancer. In: Prostatic Tumor Markers, Urologic Clinics of North America. Edited by Joseph Oesterling.
  54. Schutz M and Crawford ED: Testis Tumors. In: Surgical Decision Making. Edited by Norton, Steele and Eiseman. W. B Saunders, pp. 286-87, 1993.
  55. Schutz MJ and Crawford ED: Laparoscopic Lymph Node Dissection. In: Prostate Cancer, Edited By S Das and ED Crawford, Mosby, 1992.
  56. Mayer FJ and Crawford ED: Optimal Therapy for Metastatic Prostate Cancer. In: Recent Advances in Urology/Andrology by Hendry and Kirby. Churchill Livingstone Co., pp 159. 1993.
  57. Schutz MJ and Crawford ED: Laparoscopic Pelvic Lymphadenectomy. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY. 1993.
  58. Daneshgari F and Crawford ED: Endocrine Therapy of Advanced Carcinoma of the Prostate. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
  59. DeAntoni EP and Crawford ED: Chemoprevention of Prostate Cancer: Issues and Controversies. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
  60. Das S and Crawford ED: Carcinoma of the Prostate: Future Perspectives. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
  61. Vestal C and Crawford ED: Laparoscopic Retroperitoneal Lymph Node Dissection. In: Urologic Laparoscopy. S Das and E.D Crawford EDs. W. B. Saunders Company, Philadelphia, PA, 1994.
  62. Crawford ED, DeAntoni ED: Early Detection of Prostate Cancer: Challenges and Controversies. In: Early Detection of Cancer: Molecular Markers by Srivastava, S, Lippman SM, Hong, WK, and Mulshine, JL. Futura Publishing Co, Inc., Armonk, NY, 1994.
  63. Schutz MJ and Crawford ED: Prostate Adenocarcinoma -- The Management of Metastatic Disease. In: Clinical Urology. Edited by Krane, Siroky, and Fitzpatrick. JB Lippincott Co., Philadelphia, 1994.
  64. Crawford ED: Leuprolide. In: Therapeutic Drugs. Edited by Sir Colin Dollery. Churchill Livingston Co., 1994.
  65. Mayer FJ and Crawford ED: Update on Combined Androgen Blockade for Metastatic Prostate Cancer. In: Advances in Urology, Vol 7. Mosby Year Book, Inc. 1994.
  66. Mayer FJ and Crawford ED: The Prostate. In: Haskell’s Cancer Treatment, 4th ed. WB Saunders, Philadelphia, PA, 1995.
  67. Mayer FJ and Crawford ED: The Role of Endocrine Therapy in the Management of Local and Distant Recurrence of Prostate Cancer Following Radical Prostatectomy or Radiation Therapy. In: Evaluation and Management of Recurrent Malignant Disease, 1994.
  68. Crawford ED: Is It Safe to Delay Treatment of This Patient with Low Grade Prostatic Carcinoma? In: Cancer Consultations, Vol 1, edited by Abeloff, MD and Wittes, RE. APRR Public, Huntington, NY, 1994.
  69. Crawford ED: Screening des Prostatakarzinoms dokumentiert den Wert des PSA-Tests und fuhrt zur Bestatigung von Risikofaktoren. In: Screening des Prostatakarzinoms, by Faul and Altwein. Springer-Verlag, Berlin/Heidelberg/New York, 1995.
  70. Waxman S and Crawford ED: Advanced Prostate Cancer. In: Surgical Technology International IV. Universal Medical Press, Inc., San Francisco, California, 1995.
  71. Levin R and Crawford ED: Bladder, Renal, Pelvis and Uretral Cancers. In: Haskell’s Cancer Treatment, 4th ed. WB Saunders, Philadelphia, PA, 1995.
  72. Das S and Crawford ED: Laparoscopic Surgery in Urologic Oncology. In: Seminars in Surgical Oncology.
  73. Waxman S and Crawford ED: Advanced Prostate Cancer. In: Surgical Techniques (International IV). Universal Medical Press Inc., San Francisco, CA, 1995.
  74. Crawford ED and Debruyne FMJ: (Monograph) Superficial Bladder Cancer: Diagnosis and Treatment with Intravesical Agents. In: Bristol-Myers Squibb Oncology Medical Educational Services Update, June, 1996.
  75. Crawford ED, Donohue RE, and Davis M: Diseases of the Prostate. In: Geriatric Medicine, 2d ed. DW Jahnigen and RW Schrier, eds. Blackwell Science, Cambridge, Massachusetts, 1996.
  76. Heppe RK and Crawford ED: Radical Nephrectomy -- Thoracoabdominal Intrapleural Approach. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
  77. Crawford ED: Radical Retropubic Prostatectomy -- Antegrade Approach. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
  78. Crawford ED and Wolach M: Salvage Cystectomy and Perineal Cystoprostatectomy. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
  79. Cox RL and Crawford ED: Carcinoma of the Penis -- Management of the Regional Lymph Drainage. In: Current Genitourinary Cancer, 2nd ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
  80. DeAntoni EP and Crawford ED: Hormonal Therapy for Advanced Carcinoma of the Prostate. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
  81. Hussain MH and Crawford ED: Androgen Deprivation Strategies for Metastatic Prostate Cancer. In: Principles and Practice of Genitourinary Oncology. D Raghavan, S Leibel, H Scher, and P Lange, eds. Lippincott-Raven, Philadelphia, Pennsylvania, 1997.
  82. Stenner J and Crawford ED: Combined Androgen Blockade. In: Prostate Cancer. AV Kaisary, G Murphy, L Denis, and K Griffiths, eds. Martin Dunitz, London, England, 1997.
  83. Waxman S and Crawford ED: Metastatic Adenocarcinoma of the Prostate (TxNxM+): Management and Prognosis. In: Urologic Oncology. JE Oesterling and JP Richie, eds. W.B. Saunders Company, Philadelphia, 1997.
  84. Crawford ED: Combined Androgen Blockade: Clinical Basis. In: New Perspectives in Prostate Cancer. A Belldegrun, RS Kirby, and T Oliver, eds. Isis Medical Media, Ltd., Oxford, UK, 1998.
  85. McLeod DG, Crawford ED and DeAntoni EP: Combined Androgen Blockade: The Gold Standard of Metastatic Prostate Cancer. In: Management of Prostate Cancer. CC Schulman and ED Crawford EDs. European Urology, Brussels, Belgium, 1998.
  86. Ziada A and Crawford ED: TxNxM1: The Case for Total Androgen Deprivation. In: Advanced Treatment of Prostatic Diseases. MI Resnick and IM Thompson, eds. 1999.
  87. Crawford ED: The Utility of Prostate Specific Antigen as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials. In: Strategies for the Chemoprevention of prostate Cancer. CC Schulman and GJ Kelloff, eds. S Karger, AG, Basel, Switzerland, 1999.
  88. Ziada A and Crawford ED: Intravesical Chemotherapy of Bladder Cancer. In: Bladder Cancer: Biology, Diagnosis, and Management. KN Syrigos and DG Skinner, eds. Oxford University Press, Inc., New York, 1999.
  89. Stenner JI, Rosenblum, M, and Crawford ED: Treatment of Advanced (Stage T1-4NXM+) Prostate Cancer. In: Prostate Diseases. H Lepor, ed. W.B. Saunders Company, Philadelphia, PA, 1999.
  90. Ziada A, Rosenblum M, and Crawford ED: Hormonal Therapy – Neoadjuvant, Adjuvant, Definitive, and Intermittent. In:  Current Clinical Urology: Management of Prostate Cancer. EA Klein, eds. Humana Press, Inc, Totowa, NJ, 2000.
  91. Abouelfadel Z and Crawford ED: Experience of Prostate Cancer Awareness Week. In: Prostate Cancer Screening. IM Thompson, MI Resnick, and EA Klein, eds. Humana Press, Totowa, NJ, 2000.
  92. Crawford ED and Waxman S: The History of Prostate Specific Antigen. In: Prostate Specific Antigen. Michael K. Brawer, editor. Marcel Dekker, Inc, New York, NY, 2001.
  93. Leewansangton S and Crawford ED: Prostate. In: Cancer Treatment, (fifth ed). CM Haskell, editor. W.B. Saunders Company, Philadelphia, PA, 2001.
  94. Leewansangton S and Crawford ED: Bladder, Renal Pelvis and Ureters. In: Cancer Treatment, (fifth ed). CM Haskell, editor. W.B. Saunders Company, Philadelphia, PA, 2001.
  95. Gamito EJ, Crawford ED, and Errejon A: Artificial Neural Networks for Predictive Modeling in Prostate Cancer. In: Prostate Cancer, Science and Clinical Practice. Jack H. Mydlo and Ciril J. Godec, eds. Academic Press/Elsevier, Oxford, Great Britain, 2003.
  96. Akduman, A and Crawford ED: Radical Prostatectomy, The Retrograde Antegrade Approach. In: Prostate Cancer, Science and Clinical Practice. Jack H. Mydlo and Ciril J. Godec, eds. Academic Press/Elsevier, Oxford, Great Britain, 2003.
  97. Wilson SS and Crawford ED: Screening for Prostate Cancer: Current Recommendations. In: Urologic Clinics of North America. Vol 31(2) 219-226 Elsevier Science, Great Britain, May 2004.
  98. Akduman B, Errejon A, and Crawford ED: Use of PSA to Evaluate Risk and Progression of Prostate Cancer. In: Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention. G. J. Kelloff, E. T. Hawk and C. C. Sigman eds. Humana Press, Inc. Totowa, NJ. 2004.
  99. Crawford ED, Holzbeierlein JM, Krongrad A, Maroni PD, and Thrasher JB: Surgery. In: American Cancer Society’s Complete Guide to Prostate Cancer.  David G. Bostwick, MD, E. David Crawford, MD, Celestia S. Higano, MD and Mack Roach III, MD eds. American Cancer Society, Health Promotions, Atlanta, GA 30329, 2004.
  100. Oottamasathien S and Crawford ED: Testis Tumor. In: Surgical Decision Making, 5th Edition. Robert C. McIntyre Jr. MD, Gregory v. Stiegmann, MD and Ben Eiseman, MD eds. Elsevier Saundrs, Philadelphia, PA, 2004.
  101. Crawford ED: Editorial Commentary: Donald L. Trump, MD: Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy: When? In: Management of Prostate Cancer – Advances and Controversies. Kenneth B. Cummings ed. Marcel Dekker, New York, NY, 2005.
  102. Maroni PD, Thrasher JB, and Crawford ED: Advanced Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology, 3rd Edition. Nicholas Vogelzang, Peter Scardino, William Shipley, Frans Debruyne, W. Marston Linehan eds. Lippincott, Williams and Wilkins, Philadelphia, PA 2006.
  103. Phillips JM, Crawford ED: The Changing Landscape of Prostate Cancer Chemoprevention: Current Strategies and Future Directions. In: Cancer Prevention- From Mechanisms to Translational Benefits. Alexandros Georgakilas, editor. InTech, 2012.
  104. Dupuy DE, Fong Y, McMullen WN, Et all. (E. David Crawford listed at section editor). Image-Guided Cancer Therapy: A Multidisciplinary Approach. New York, 2013.

Book Reviews

  1. The Prostatic Cell: Structure and Function (GP Murphy, AA Sandberg, and JP Karr). Reviewed for Oncology Times, 4(9):2, 1982.
  2. Prostate Cancer (GM Jacobi and R Hohenfellner). Reviewed for Oncology Times, 4(11):25, 1982.
  3. Progress in Clinical and Biologic Research, Vol. 2, 69: Progress and Controversies in Oncological Urology, II. (FH Schroder, GM Klin, KH Kurther, et al.). Reviewed for Journal of the National Cancer Institute, 1988.
  4. Uro-oncology: Current Status and Future Trends (HGW Fromuller and MP Wirth, eds.). M.   Schutz and ED Crawford: Reviewed for Journal of the National Cancer Institute, 1991.
  5. Doxazosin Gastrointestinal Therapeutic System: A Review of its Use in Benigh Prostatic Hyperplasia (Goldsmith DR, Plosker GL).  Reviewed for Drugs, 65 (14), 2005.

 

Autoimmune Journal Flyer